Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Edgewise Therapeutics Announces Proposed $100M Offering Of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ:EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common
Edgewise Therapeutics Announced 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy; Announced Significant Decrease in Levels of Serum Creatine Kinase and Fast Skeletal Muscle Troponin I
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories –
– Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD –
– EDG-5506 continues to be well-tolerated with no serious adverse events observed –
Goldman Sachs Downgrades Edgewise Therapeutics to Sell, Announces $5 Price Target
Goldman Sachs analyst Madhu Kumar downgrades Edgewise Therapeutics (NASDAQ:EWTX) from Neutral to Sell and announces $5 price target.
Edgewise’s Dystrophy Candidate Lowers Muscle Damage Biomarkers
Edgewise Therapeutics Inc (NASDAQ:EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). …
Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Lowers Price Target to $5
Goldman Sachs maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and lowers the price target from $8 to $5.
Analyst Ratings for Edgewise Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
